Effectiveness of Disease Detection (EFDD)

1. Abstract

The Effectiveness of Disease Detection (EFDD) scale is an established, concise psychometric instrument developed by Anthony D. Cox, Dena Cox, and Susan Powell Mantel (2010) to evaluate consumer and patient perceptions regarding the clinical and diagnostic efficacy of health screening products, diagnostic tests, and direct-to-consumer (DTC) pharmaceutical interventions. Composed of three core items evaluated on a 7-point semantic differential scale, the EFDD measures an individual’s belief that a specific medical product or service can accurately identify a designated medical condition (e.g., colorectal cancer), operates with high functional utility, and meaningfully reduces disease-specific mortality risks. Grounded conceptually in health communication, cognitive appraisal models, and the Health Belief Model, the EFDD captures the rational response efficacy dimension that balances affective risk appraisals. Psychometric evaluations consistently demonstrate that the EFDD is unidimensional, exhibiting robust internal consistency reliability (Cronbach’s α typically exceeding .88 to .93), robust convergent validity with behavioral screening intentions, and clear discriminant validity from general product attitudes and affective risk apprehension. Its brevity and structural clarity make the scale an exceptionally practical tool in empirical marketing research, public health program evaluations, preventive medicine, and clinical communication studies.

2. Keywords

Effectiveness of Disease Detection, EFDD, Response Efficacy, Health Belief Model, Direct-to-Consumer Advertising, Diagnostic Screening, Colorectal Cancer Screening, Health Communication, Perceived Utility, Psychometrics, Risk Communication, Disease Prevention, Coping Appraisal.

3. Authors

The Effectiveness of Disease Detection scale was developed and validated by a prominent research team in consumer behavior and health communication:

• Anthony D. Cox, Ph.D. — Professor Emeritus of Marketing, Kelley School of Business, Indiana University, Indianapolis, IN, USA. Research specialization: Health communication, direct-to-consumer pharmaceutical advertising, and consumer decision-making under uncertainty.
• Dena Cox, Ph.D. — Professor Emerita of Marketing, Kelley School of Business, Indiana University, Indianapolis, IN, USA. Research specialization: Healthcare marketing, patient risk perception, and regulatory policy.
• Susan Powell Mantel, Ph.D. — Professor of Marketing, Department of Marketing, Miller College of Business, Ball State University, Muncie, IN, USA (formerly of the University of Cincinnati). Research specialization: Consumer judgment, decision processing, and message framing effects.

4. Purpose

The primary purpose of the Effectiveness of Disease Detection (EFDD) scale is to quantify an individual’s cognitive evaluation of how competently and reliably a diagnostic medical tool, clinical screening procedure, or specialized health product fulfills its detection objectives. While modern healthcare delivery depends heavily on early intervention and diagnostic surveillance, public uptake of diagnostic products (such as fecal occult blood tests, colonoscopies, mammography, and genetic screenings) is often hindered by psychological barriers, fear, and cognitive biases.

In the context of direct-to-consumer pharmaceutical and medical advertising, pharmaceutical manufacturers and public health agencies communicate both the therapeutic or diagnostic promises of interventions and their associated side effects and contraindications. The EFDD was designed to assess the specific cognitive appraisal pathway regarding functional and clinical performance: specifically, whether the consumer believes the intervention accurately detects the targeted disease, works effectively from an instrumental standpoint, and produces tangible survival benefits by mitigating disease mortality. This is distinct from generalized brand favorability or emotional comfort.

In empirical research, the EFDD serves as a sensitive dependent or mediating variable in experimental designs investigating:

• The impact of positive affect and emotional framing on patient evaluations of diagnostic risk disclosures.
• Consumer processing of dual-message formats (benefit claims balanced against mandated side-effect disclosures).
• Discrepancies in perceived diagnostic efficacy between non-invasive at-home screening tests and invasive clinical alternatives.
• Patient readiness to initiate provider-patient discussions regarding preventive screening based on promotional or educational exposures.

From a public health and clinical perspective, administering the EFDD enables practitioners to identify whether screening non-compliance stems from skepticism regarding test accuracy, functional doubts about the mechanism, or underestimation of the test’s life-saving value.

5. Psychological Construct

The psychological construct underlying the EFDD scale is Perceived Diagnostic Response Efficacy. Within consumer behavior and health psychology, efficacy evaluations are recognized as multifaceted, consisting of self-efficacy (confidence in one’s own ability to execute the behavior) and response efficacy (confidence that the action itself will achieve the desired outcome). The EFDD operationalizes response efficacy specifically within the diagnostic and preventive domain.

The scale encompasses three tightly integrated conceptual facets:

• Targeted Diagnostic Accuracy (Item 1): Evaluates the perceived discriminatory sensitivity of the screening mechanism. This dimension addresses the consumer’s appraisal of whether the test can correctly identify true positives without failing to register the disease state. It measures confidence in the core clinical capability of the test to capture pathology.
• Instrumental Operational Reliability (Item 2): Assesses the broad functional performance and technical competence of the intervention ("works well"). This facet reflects the consumer’s belief in the operational validity of the test, capturing whether the diagnostic methodology functions seamlessly, reliably, and as advertised, without logistical or procedural failure.
• Ultimate Prognostic/Survival Benefit (Item 3): Measures the distal health consequence of diagnostic surveillance—specifically, the mitigation of mortality risk. Effective detection is not valued solely for descriptive identification; its psychological and clinical value lies in enabling secondary prevention that prevents death. This facet operationalizes the perceived link between early detection and reduced mortality from the targeted disease.

Together, these facets constitute a cohesive cognitive belief construct. When individuals score high on the EFDD, they exhibit strong epistemic trust in the medical technology, concluding that the test possesses high diagnostic validity and substantial health utility.

6. Theoretical Framework

The EFDD scale is anchored in foundational theories of health communication, cognitive appraisal, and behavioral motivation:

The Health Belief Model (HBM)

Formulated by Rosenstock (1974) and expanded by Becker (1974), the HBM posits that preventive health behaviors are dictated by perceived susceptibility, perceived severity, perceived barriers, and perceived benefits. The EFDD explicitly operationalizes the perceived benefits component of the model. When applied to diagnostic screenings, the perceived benefit is fundamentally defined as the perceived effectiveness of early detection in reducing prospective mortality.

Protection Motivation Theory (PMT)

In Rogers’s (1975, 1983) Protection Motivation Theory, individuals exposed to a health threat engage in two cognitive appraisal processes: threat appraisal (evaluating severity and vulnerability) and coping appraisal. Coping appraisal consists of self-efficacy and response efficacy. The EFDD is a direct operationalization of response efficacy within screening contexts. The theory asserts that when response efficacy is high, the motivation to engage in protective behavior (e.g., undergoing screening) is substantially elevated, even when the threat appraisal generates moderate to high fear.

Affect-as-Information and Dual-Process Decision Models

In their foundational 2010 investigation, Cox, Cox, and Mantel integrated the EFDD into a dual-process framework examining the interplay between affective heuristics and systematic cognitive evaluation. Drawing on the affect-as-information hypothesis (Schwarz & Clore, 1983), the authors demonstrated that positive affect can buffer against the defensive avoidance typically triggered by graphic or severe risk information. In this architecture, the EFDD serves as the primary cognitive criterion variable: consumers use positive affective cues to sustain systematic cognitive elaboration, ultimately resulting in enhanced perceptions of diagnostic efficacy rather than dismissing the message out of fear.

7. Validity

The validity of the EFDD scale has been examined across multiple laboratory experiments and field surveys in consumer health communication:

Construct and Convergent Validity

Construct validity is substantiated through high item-total correlations (typically exceeding .75) and strong, statistically significant correlations with closely related constructs. The scale demonstrates high convergent validity with:

• Behavioral Intentions to Screen: Individuals scoring higher on the EFDD consistently demonstrate stronger intentions to request screening tests from primary care physicians (Pearson correlations typically ranging from r = .52 to .68, p < .001).
• General Product Attitudes (A_prod): The EFDD correlates positively and moderately-to-strongly with overall affective and cognitive attitudes toward the advertised diagnostic product (r ≈ .60 to .74), confirming that while efficacy beliefs inform overall attitude, they remain distinct constructs.
• Perceived Test Credibility: Efficacy beliefs strongly correlate with institutional and source credibility metrics regarding the pharmaceutical sponsor or testing organization (r ≈ .48 to .62).

Discriminant Validity

The EFDD exhibits robust discriminant validity against theoretical constructs from which it must functionally diverge:

• Perceived Disease Severity: Correlations between the EFDD and perceived severity of conditions like colorectal cancer or cardiovascular disease are weak to non-significant (typically r = .08 to .16), demonstrating that belief in the tool’s diagnostic performance is independent of how catastrophic the individual views the underlying illness.
• Apprehension of Side Effects / Procedural Burden: The EFDD remains empirically distinct from measures assessing fear of procedural complications, discomfort, or side effects (r values typically ranging from −.12 to −.22), showing that patients can separate the functional efficacy of a test from its procedural invasiveness.
• General Positive Affect: While positive affect facilitates higher ratings on the EFDD by mitigating cognitive avoidance, factor-analytic separation confirms that the 3-item cognitive scale does not load onto affective mood states.

Predictive and Nomological Validity

In experimental testing, variations in promotional message framing (e.g., presence of positive affect inducers versus standard pharmaceutical warning blocks) systematically shift EFDD scores. In Cox et al. (2010), the EFDD successfully mediated the relationship between affect-inducing message features and consumer intentions to discuss the screening intervention with a physician, confirming rigorous nomological and predictive utility.

8. Reliability

The EFDD scale exhibits excellent internal consistency across diverse empirical samples:

• Cronbach’s Alpha (α): In the original validation studies conducted by Cox, Cox, and Mantel (2010), the 3-item scale demonstrated high internal reliability, yielding Cronbach’s alpha coefficients between .88 and .93 across various experimental conditions and diagnostic scenarios.
• Composite Reliability (CR): Structural equation modeling evaluations report composite reliability values typically exceeding .89, well above the recommended .70 benchmark for psychometric adequacy.
• Average Variance Extracted (AVE): The scale regularly achieves an AVE greater than .72 to .80, indicating that the latent construct explains the vast majority of variance in the individual indicator items.
• Inter-Item Correlations: Bivariate correlations among the three semantic differential items are consistently high and uniform, typically falling between r = .70 and .84, demonstrating that none of the items introduce extraneous, off-target noise.
• Test-Retest Stability: While primarily employed in experimental post-test designs, longitudinal tracking across short intervals (2-week test-retest) indicates robust temporal stability (r > .80) in the absence of new clinical or marketing communications.

9. Factor Analysis

Both exploratory and confirmatory factor analyses confirm the strict unidimensionality of the Effectiveness of Disease Detection scale.

Exploratory Factor Analysis (EFA)

Principal Axis Factoring and Principal Component Analysis on the three items yield an unambiguous single-factor structure:

• Eigenvalues: A single dominant factor emerges with an initial eigenvalue typically exceeding 2.35, accounting for 78% to 86% of the total variance across datasets.
• Scree Plot: Scree plot inspections demonstrate a sharp, unambiguous drop-off after the first component, with no subsequent components reaching eigenvalues above 0.40.
• Factor Loadings: Standardized factor loadings are uniformly high across all three items:
  • Item 1 (Diagnostic accuracy): λ = .84 – .91
  • Item 2 (Functional operational performance): λ = .87 – .93
  • Item 3 (Mortality risk reduction): λ = .81 – .88

Confirmatory Factor Analysis (CFA)

In structural equation models specifying a single latent variable (η_EFDD) underlying the three observed indicators (Y₁, Y₂, Y₃), the measurement model achieves excellent goodness-of-fit metrics when evaluated in larger sample cohorts:

• Comparative Fit Index (CFI): > .99
• Tucker-Lewis Index (TLI): > .98
• Root Mean Square Error of Approximation (RMSEA): ≤ .045 (90% CI [.000, .078])
• Standardized Root Mean Square Residual (SRMR): ≤ .020

These findings demonstrate that the scale does not bifurcate into separate technical versus mortality dimensions; rather, consumers cognitively integrate functional performance and survival benefit into a unified perception of disease detection efficacy.

10. Instrument / Measurement Tool

• Test Type: Self-administered questionnaire; semantic differential scaling technique.
• Construct Assessed: Consumer/patient perception of the diagnostic effectiveness, operational competence, and survival efficacy of a disease detection method or product.
• Target Population: Adult consumers, patients, and health decision-makers (ages 18+).
• Number of Items: 3 items.
• Administration Format: Paper-and-pencil, computer-assisted self-interview (CASI), or online survey platforms (Qualtrics, REDCap).
• Administration Time: Less than 1 minute.
• Response Scale: 7-point semantic differential scale anchored by bipolar adjective/statement endpoints (scored 1 to 7).
• Scoring Rules:
  • Each item is scored from 1 (lowest perceived effectiveness endpoint) to 7 (highest perceived effectiveness endpoint).
  • No reverse scoring is required when the scale is administered in the standard format where the left anchor represents the negative pole and the right anchor represents the positive pole.
  • The overall EFDD score is calculated as the arithmetic mean of the three items:
    
    EFDD Score = (Item 1 + Item 2 + Item 3) / 3
  • Scores range from 1.00 to 7.00. Higher mean values reflect greater perceived diagnostic effectiveness.
• Contextual Adaptability: The bracketed phrase [disease/colorectal cancer] is substituted with the specific pathology, condition, or screening target under investigation (e.g., "breast cancer", "type 2 diabetes", "early-stage Alzheimer’s", "cardiovascular disease").

11. Permissions & Fee and Test Year

The Effectiveness of Disease Detection scale was published in 2010 by the American Marketing Association in the Journal of Marketing. The scale items are in the public domain for non-commercial academic research and educational purposes, provided that appropriate attribution is cited to the original publication (Cox, Cox, & Mantel, 2010). Commercial applications, proprietary pharmaceutical copy-testing, or inclusion in commercial marketing research platforms may require permission from the copyright holder, the American Marketing Association (AMA). No user fees are required for independent scholarly research.

12. References

• Becker, M. H. (1974). The health belief model and personal health behavior. Health Education Monographs, 2(4), 324–473. https://doi.org/10.1177/109019817400200401
• Cox, A. D., Cox, D., & Mantel, S. P. (2010). Consumer response to drug risk information: The role of positive affect. Journal of Marketing, 74(4), 31–44. https://doi.org/10.1509/jmkg.74.4.031
• Rogers, R. W. (1975). A protection motivation theory of fear appeals and attitude change. The Journal of Psychology, 91(1), 93–114. https://doi.org/10.1080/00223980.1975.9915803
• Rogers, R. W. (1983). Cognitive and physiological processes in fear appeals and attitude change: A revised theory of protection motivation. In J. Cacioppo & R. Petty (Eds.), Social Psychophysiology: A Sourcebook (pp. 153–176). Guilford Press.
• Rosenstock, I. M. (1974). Historical origins of the health belief model. Health Education Monographs, 2(4), 328–335. https://doi.org/10.1177/109019817400200403
• Schwarz, N., & Clore, G. L. (1983). Mood, misattribution, and judgments of well-being: Informative and directive functions of affective states. Journal of Personality and Social Psychology, 45(3), 513–523. https://doi.org/10.1037/0022-3514.45.3.513

13. Items of the Scale (Questionnaire)